home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Effective Treatment For Rheumatoid Arthritis

 
  July, 2 2001 2:23
your information resource in human molecular genetics
 
     
Effective Treatment For Rheumatoid Arthritis

Chronic inflammatory diseases, such as rheumatoid arthritis, involve autoimmune destruction of self-tissues by cells of the immune system that have somehow lost the ability to recognize friend from foe. Lymphocytes that make antibodies and those that trigger cell-mediated responses - B cells and T cells, respectively - contribute to this pathology. Any therapeutic strategies to treat patients with such diseases must therefore be able to inhibit activation of both cell types. The identification of such dual-purpose targets has been elusive. However, in the July issue of Nature Immunology (Vol. 2, No. 7, pages 632-637), researchers at Genentech in San Francisco have been able to inhibit B and T cells and halt disease in a mouse model of arthritis.

Immune cells respond to signals perceived in their environment by means of various receptors on their surface. Some signals promote cell activation, as required for battling infections, whereas others turn off this response. Ashkenazi and colleagues have focused on inhibiting interactions that activate lymphocytes, by confusing the system with “decoy” molecules. Specifically, they targeted the signaling molecule BLyS, which turns out to activate T cells, and not just B cells, through one of BLyS’s two or more receptors, TACI. Administration of soluble TACI blocked BLyS function and prevented the development of arthritis in mice. Thus, these signaling molecules are potential targets for developing new treatments for arthritis and other inflammatory diseases.

A News & Views (pages 577-578) on this article was written by Michael J. Lenardo of the National Institutes of Health, Bethesda, Maryland.

Avi Ashkenazi
Genentech, Inc.
Dept of Molecular Oncology
1 DNA Way
South San Francisco, CA 94080
UNITED STATES
Tel: (+1) 650-225-1853
Fax: (+1) 650-225-6443
aa@gene.com

Michael J. Lenardo
National Institutes of Health
Institute of Allergy & Infectious Diseases
Room 11N311, Building 10
10 Center Drive, MSC1892
Bethesda, MD 20892-1892
UNITED STATES
Tel: (+1) 301-496-6754
Fax: (+1) 301-402-8530
lenardo@nih.gov

(C) Nature Immunology press release.


Message posted by: Trevor M. D'Souza

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.